Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

GlobeNewswireOct 25 19:05

Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11

Futu NewsOct 11 20:34 · Ratings

Insiders At Y-mAbs Therapeutics Sold US$4.5m In Stock, Alluding To Potential Weakness

Simply Wall StSep 27 21:10

While Shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate

Yahoo FinanceSep 25 21:29

Y-mAbs Therapeutics Signs Lease Deal for New Jersey Property

MT NewswiresSep 18 05:57

Analysts Offer Insights on Healthcare Companies: Tilray (TLRY) and Y-Mabs Therapeutics (YMAB)

TipRanksSep 11 17:04